Biomatter raises $18 million for AI enzyme design
Biomatter has raised $18 million in Series A funding to expand its AI enzyme design platform. A planned Vilnius facility aims to shorten enzyme development from weeks to days.
By Made in 10 Newsroom
Biomatter, based in Vilnius, raised the funding round led by Astanor, with existing investors UVC Partners, Inventure and Metaplanet participating. It plans to open a 2,000-square-metre enzyme design and testing facility in 2027. The money will also support a larger commercial team and expansion in the United States.
